•Dr. Reddy's Laboratories announced a temporary delay in commercial supplies of semaglutide injection due to a scale-up issue with the active pharmaceutical ingredient.
•Management emphasized that products already in the market are unaffected, with no patient safety concerns or risk of product recall.
•Ripple CEO Brad Garlinghouse revealed the company seriously considered shutting down and distributing XRP holdings to shareholders following the SEC lawsuit.